La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company, a biopharmaceutical company, develops pharmaceutical products to treat patients with lupus. The company's lead product in development is Riquent, which is in Phase 3 ASPEN clinical trials to treat patients with lupus. The Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. It also discovers and develops orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. The company was founded in 1989 and is based in San Diego, California.